Renal cell carcinoma (RCC) is a common malignancy of the urinary system, characterized by insidious early manifestations, marked heterogeneity, and a high risk of postoperative recurrence or metastasis in some patients. Current expert consensus indicates that conventional tissue biopsy and imaging modalities have inherent limitations in dynamic disease monitoring and the assessment of tumor heterogeneity. Due to its minimal invasiveness, repeatability, and capacity for real-time dynamic evaluation, liquid biopsy has become an important focus in precision oncology. Circulating tumor cells, circulating tumor DNA, exosomes, and non-coding RNAs are regarded as key liquid biopsy biomarkers in RCC. Among these, circular RNAs, long non-coding RNAs, and microRNAs have attracted increasing attention because of their relative stability and well-characterized regulatory functions, demonstrating considerable potential in the diagnosis, treatment monitoring, and prognostic assessment of RCC. Based on the latest evidencebased evidence and clinical practice from China and abroad, this consensus summarizes the current research and clinical utility of noncoding RNAs in liquid biopsy for RCC, and formulates five key consensus statements. These are intended to offer Chinese urologists more explicit references and standardized advice for the prevention and treatment of RCC, thereby further enhancing patient benefit.